LL-37 is a human cathelicidin antimicrobial peptide with emerging research in immune modulation, wound healing, and inflammation regulation. Using it requires reconstitution, precise dosing, and provider oversight. TelosRX can evaluate whether LL-37 fits your protocol.
Important: LL-37 is an investigational peptide available as a compounded formulation. It is not FDA-approved. Use requires evaluation and approval by a licensed provider. The information below is educational and does not constitute a prescription or clinical recommendation.
Step 1: Understand What LL-37 Is and How It Works
LL-37 (also written hCAP-18/LL-37) is the only human cathelicidin identified to date. It is produced naturally by neutrophils, keratinocytes, and epithelial cells and serves as a first-line defense peptide against bacteria, viruses, and fungi while also modulating the inflammatory cascade.
Research published in peer-reviewed immunology journals has characterized LL-37’s dual role: antimicrobial (direct membrane disruption of pathogens) and immunomodulatory (regulating NF-κB signaling, stimulating mast cell release, and modulating dendritic cell differentiation).
Key documented activities in preclinical and early clinical research:
- Antimicrobial activity against gram-positive and gram-negative bacteria
- Promotion of wound healing and re-epithelialization (human skin trials)
- Modulation of inflammatory cytokine profiles (TNF-α, IL-6 downregulation in some contexts)
- Antiviral activity demonstrated against respiratory syncytial virus and influenza A in vitro
Understanding the mechanism is the starting point for informed use — which begins with a provider conversation, not a self-directed protocol.
Step 2: Get a Provider Evaluation Before Starting
Because LL-37 affects immune pathways, it is not appropriate for self-directed use without medical supervision. Conditions where LL-37 may be contraindicated or require extra caution include autoimmune diseases (where immune stimulation could exacerbate symptoms), active inflammatory skin conditions, and concurrent use of immunosuppressant medications.
A TelosRX provider can review your health history, current medications, and treatment goals asynchronously — no phone call or in-person visit required. Approval is subject to that evaluation; it is not guaranteed. Submit your health intake at TelosRX to begin the evaluation process.
Step 3: Reconstitute the Lyophilized Peptide Correctly
LL-37 from a compounding pharmacy is typically supplied as a lyophilized (freeze-dried) powder in a sterile vial. Reconstitution requires bacteriostatic water (BAC water) — not sterile water for injection, as the bacteriostatic agent (benzyl alcohol) extends shelf life after reconstitution.
General reconstitution steps (follow your pharmacy’s specific instructions):
- Allow the vial to reach room temperature before opening (approximately 10–15 minutes).
- Wipe the vial stopper with an alcohol swab and allow to air dry.
- Draw the prescribed volume of BAC water into a sterile insulin syringe.
- Inject the BAC water slowly into the vial, directing it along the vial wall rather than onto the powder cake.
- Gently swirl — do not shake — until the powder is fully dissolved. The solution should be clear.
- Label the vial with the date and concentration, and refrigerate immediately (2–8°C / 36–46°F).
Reconstituted LL-37 is typically stable refrigerated for 14–21 days, depending on the compounding pharmacy’s formulation specifications. Discard if turbid, discolored, or past the labeled expiration.
Step 4: Understand Dosage Ranges and Protocols in Research
There is no FDA-approved dosing standard for LL-37. The ranges cited below reflect investigational protocols published in peer-reviewed literature and compounding pharmacy guidance — not a clinical recommendation:
| Application Area | Reported Research Range | Route |
|---|---|---|
| Immune modulation / general wellness | 50–100 mcg per injection, 3–5x per week | Subcutaneous |
| Wound healing support (investigational) | 50–200 mcg, topical or subcutaneous near wound site | Topical or SC |
| Autoimmune conditions (research only) | Highly variable; no consensus protocol established | Varies |
Your provider will set the specific dose, frequency, and duration based on your individual evaluation. Do not adjust dose without consulting your provider.
Step 5: Administer Subcutaneous Injections Safely
If your provider approves subcutaneous administration:
- Wash hands thoroughly with soap and water for at least 20 seconds.
- Prepare the injection site: rotate between the abdomen (2 inches from the navel), outer thigh, or back of the upper arm.
- Wipe the site with an alcohol swab and allow to dry for 10 seconds.
- Draw the prescribed dose from the reconstituted vial using a sterile insulin syringe (typically 28–31 gauge).
- Pinch a small fold of skin, insert the needle at a 45–90 degree angle (depending on tissue depth), and inject slowly.
- Withdraw the needle and apply light pressure. Do not rub.
- Dispose of the syringe in a sharps container immediately after use.
Step 6: Monitor and Report Side Effects to Your Provider
LL-37 is generally well-tolerated in published research, but individual responses vary. Reported side effects include:
- Mild injection site redness or swelling (common, typically resolves within hours)
- Transient fatigue or flu-like symptoms in early cycles (less common)
- Inflammatory flares in individuals with underlying autoimmune conditions
Contact your provider asynchronously through your TelosRX portal if you notice unusual swelling, rash, worsening of an existing inflammatory condition, or systemic symptoms. Do not discontinue without provider guidance.
What to Expect: Timeline of LL-37 Effects
Published research on LL-37 does not support a fixed “results by week X” timeline. Reported observations from investigational use:
- Weeks 1–2: Injection site reactions (if any) most likely in this phase. Some users report increased energy or mild immune-activation symptoms.
- Weeks 4–8: Wound healing studies reported measurable changes in re-epithelialization by 4–6 weeks at relevant doses.
- Weeks 8–12+: Immune modulation effects, if present, are typically assessed at this timeframe in research protocols.
Individual results vary. LL-37 is not a supplement and its effects are not predictable from self-report data. Provider-monitored protocol with outcome reassessment is the appropriate structure.
Frequently Asked Questions
Is LL-37 peptide legal to use?
LL-37 is available as a compounded peptide through licensed compounding pharmacies with a valid prescription from a licensed provider. It is not FDA-approved. Legal use requires a prescription and is subject to state and federal compounding regulations.
How is LL-37 different from BPC-157 or TB-500?
LL-37 is a human-derived antimicrobial and immune-modulating peptide. BPC-157 is a synthetic peptide with gut and tissue repair research, and TB-500 (thymosin beta-4) is associated with actin regulation and tissue regeneration. They have distinct mechanisms and research profiles and should not be self-stacked without provider oversight.
Can I take LL-37 if I have an autoimmune condition?
LL-37 modulates immune pathways and may be contraindicated or require careful dose management in people with autoimmune conditions. This is a case where provider evaluation — not self-directed use — is essential before starting.
How long should an LL-37 cycle last?
Cycle length varies by indication. Wound healing protocols in research ran 4–6 weeks. Immune modulation protocols ranged from 8–16 weeks. Your provider will determine the appropriate cycle length and whether a rest period is indicated between cycles.
Does LL-37 need to be refrigerated?
Yes. Lyophilized (unreconstituted) LL-37 should be stored at 2–8°C (refrigerated) or per the pharmacy’s instructions. After reconstitution with bacteriostatic water, it should be refrigerated and used within 14–21 days, depending on the compounding pharmacy’s specification.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.